USPTO 2015–2025 USPTO PatentsView US Corporation

Covidien LP

USPTO PatentsView assignee record — 6,485 granted patents across 183 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).

6,485
Total patents granted
183
CPC technology areas
16.2
Avg claims per patent
-5%
5-year filing velocity

Portfolio overview

Covidien LP has been granted 6,485 US utility patents between 2015 and 2025, placing Covidien LP at rank #57 across all assignees tracked by PlainPatent. This portfolio spans 183 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.2 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Covidien LP is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 70.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3,165 grants, compared with 3,320 in the 2015–2019 window — a -5% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Covidien LP's 16.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Covidien LP against peers pursuing similar technology classes.

How does Covidien compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Covidien holds 6,485 patents — placing it at rank #57 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

2004006008001,000 20152016201720182019202020212022202320242025 285
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Covidien LP patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 808 12.5%
2016 679 10.5%
2017 659 10.2%
2018 572 8.8%
2019 602 9.3%
2020 684 10.5%
2021 569 8.8%
2022 597 9.2%
2023 598 9.2%
2024 432 6.7%
2025 285 4.4%

Which technologies does Covidien LP patent most?

Top 15 of 183 technology areas

Patent Moat Analysis

Portfolio Volume Strong
Tech Breadth Diversified
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#57

Across all tracked assignees

Innovation Score

70.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Covidien LP hold?
Covidien LP holds 6,485 US granted patents filed between 2015 and 2025, spanning 183 technology areas.
What is Covidien LP's Innovation Score?
Covidien LP has an Innovation Score of 70.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Covidien LP focus on?
Covidien LP's top technology area is A61B (DIAGNOSIS; SURGERY; IDENTIFICATION) with 5,709 patents. The company has filed patents in 183 CPC subclasses total.
Is Covidien LP's patent filing rate increasing or decreasing?
Covidien LP's recent filing velocity is -5% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Covidien LP's patents?
Covidien LP's patents average 16.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Covidien LP patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope